HARMONY AND RISK: THE ROLE OF CARDIAC GLYCOSIDES IN MODERN CARDIOLOGY
Abstract
The article discusses the importance and relevance of the use of cardiac glycosides in modern cardiology, as well as the efficacy and safety of these medications in managing of cardiovascular disease. The article analyzes recent scientific literature to explore the advantages and disadvantages of using these drugs, focusing on their role in improving myocardial contractility and controlling heart electrophysiological parameters. The aims of the study are to update our understanding of cardiac glycosides and to identify potential areas for further research and clinical application.
References
Вотчал Б.Е., Слуцкий М.Е. Сердечные гликозиды. М.: Медицина; 1973.
Гегель Г.В.Ф. Наука логики. СПб.: Наука; 1997.
Глущенко В.А., Ирклиенко Е.К. Сердечно-сосудистая заболеваемость — одна из важнейших проблем здравоохранения. Медицина и организация здравоохранения. 2019;4(1):56–63.
Медик В.А., Юрьев В.К. Общественное здоровье и здравоохранение. Издание второе, исправленное и дополненное. М.: ГЭОТАР-Медиа; 2012. EDN: RPWCXZ.
Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е изд. М.: МИА; 2005.
Тимофеев Е.В., Абдалиева Ч.А., Земцовский Э.В. Опыт применения интернет-ЭКГ для оптимизации сроков госпитализации больных острым инфарктом миокарда. Педиатр. 2018;9(5):21–26. DOI: 10.17816/PED9521-26.
Федорец В.Н., Жабина Р.М., Майстренко Д.Н., Вологдина И.В., Красильникова Л.А., Василенко В.С., Овчинников И.В. Хроническая сердечная недостаточность как проявление кардиотоксичности у онкологических больных. Медицина: теория и практика. 2022;7(4):78–87.
Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. DOI: 10.15829/1560-4071-2021-4594.
Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. DOI: 10.15829/1560-4071-2020-4083.
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2024;83(1):109–279. DOI: 10.1016/j.jacc.2023.08.017.
Ahmed A., Gambassi G., Weaver M.T., Young J.B., Wehrmacher W.H., Rich M.W. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol. 2007;100(2):280–4. DOI: 10.1016/j.amjcard.2007.02.099.
Ahmed A., Rich M.W., Love T.E., Lloyd-Jones D.M., Aban I.B., Colucci W.S., Adams K.F., Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. European Heart Journal. 2006:178–186. DOI: 10.1093/eurheartj/ehi687.
Antman E.M., Wenger T.L., Butler V.P.-Jr., Haber E., Smith T.W. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744–52. DOI: 10.1161/01.cir.81.6.1744.
Bauman J.L., Didomenico R.J., Galanter W.L. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6(2):77–86. DOI: 10.2165/00129784-200606020-00002.
Butler J., Anand I.S., Kuskowski M.A., Rector T., Carson P., Cohn J.N. Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16(5):191–5. DOI: 10.1111/j.1751-7133.2010.00161.x.
Camerini A., Griffo R., Fabbri G., Aspromonte N., Ingrillì F., Lucci D., Naccarella F., Maggioni A.P. Use of digitalis in the treatment of heart failure: data from the Italian Network on Congestive Heart Failure (IN-CHF). Italian Heart Journal. 2004;5(7):523–529.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435. DOI: 10.1016/S0002-9149(88)80087-0.
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33. DOI: 10.1056/NEJM199702203360801.
Fozzard H.A., Sheets M.F. Cellular mechanism of action of cardiac glycosides. J Am Coll Cardiol. 1985;5(Suppl A):10A–15A. DOI: 10.1016/s0735-1097(85)80458-7.
Fuchs L. De historia stirpium commentarii insignes, Basileae: In officinal singriniana. 1542.
Hickey A.R., Wenger T.L., Carpenter V.P., Tilson H.H., Hlatky M.A., Furberg C.D., Kirkpatrick C.H., Strauss H.C., Smith T.W. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590–8. DOI: 10.1016/s0735-1097(10)80170-6.
Hussain Z., Swindle J., Hauptman P.J. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail. 2006;12(5):343–6. DOI: 10.1016/j.cardfail.2006.02.005.
Johnstone D., Limacher M., Rousseau M., Liang C.S., Ekelund L., Herman M., Stewart D., Guillotte M., Bjerken G., Gaasch W., Held P., Verter J., Stewart D., Yusuf S. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol. 1992;70(9):894–900. DOI: 10.1016/0002-9149(92)90734-g.
Kanji S., MacLean R.D. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527–35. DOI: 10.1016/j.ccc.2012.07.005.
Kelly R.A. Cardiac glycosides and congestive heart failure. Am J Cardiol. 1990;65(10):10E–16E; discussion 22E-23E. DOI: 10.1016/0002-9149(90)90245-v.
Kumavath R., Paul S., Pavithran H., Paul M.K., Ghosh P., Barh D., Azevedo V. Emergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics. Biomolecules. 2021;11(9):1275. DOI: 10.3390/biom11091275.
Mackenzie J. The future of medicine. London: Oxford University Press; 1919.
Newman R.A., Sastry K.J., Arav-Boger R., Cai H., Matos R., Harrod R. Antiviral Effects of Oleandrin. J Exp Pharmacol. 2020;12:503–515. DOI: 10.2147/JEP.S273120.
Škubník J., Pavlíčková V., Rimpelová S. Cardiac Glycosides as Immune System Modulators. Biomolecules. 2021;11(5):659. DOI: 10.3390/biom11050659.
SOLVD Investigators; Yusuf S., Pitt B., Davis C.E., Hood W.B., Cohn J.N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. DOI: 10.1056/NEJM199108013250501.
Sonnenblick M., Abraham A.S., Meshulam Z., Eylath U. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed). 1983;286(6371):1089–91. DOI: 10.1136/bmj.286.6371.1089.
Whitbeck M.G., Charnigo R.J., Khairy P., Ziada K., Bailey A.L., Zegarra M.M., Shah J., Morales G., Macaulay T., Sorrell V.L., Campbell C.L., Gurley J., Anaya P., Nasr H., Bai R., Di Biase L., Booth D.C., Jondeau G., Natale A., Roy D., Smyth S., Moliterno D.J., Elayi C.S. Increased mortality among patients taking digoxin — analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8. DOI: 10.1093/eurheartj/ehs348.
Withering W. An account of the foxglove and same of its medical uses, with practical remarks on dropsy, and other disease. In: Willius F.A., Keys T.E. Classics of Cardiology. New York: Henry Schuman, 1941;1:231–252.
